Suppr超能文献

大剂量噻替派联合自体骨髓挽救治疗复发性恶性少突胶质细胞瘤:一例报告

High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: a case report.

作者信息

Saarinen U M, Pihko H, Mäkipernaa A

机构信息

Children's Hospital, University of Helsinki, Finland.

出版信息

J Neurooncol. 1990 Aug;9(1):57-61. doi: 10.1007/BF00167069.

Abstract

High-dose thiotepa with autologous bone marrow rescue is a new and promising treatment modality in several kinds of solid tumors. We used this regimen in a pediatric patient who had the third recurrence of his malignant oligodendroglioma of brain that developed during '8 in 1' chemotherapy. We achieved complete response after a total dose of 1125 mg/m2 of intravenous thiotepa. Good penetration into the CNS renders thiotepa potentially useful for chemosensitive brain tumors, and one course of high-dose thiotepa can be administered with acceptable toxicity by utilizing autologous bone marrow rescue.

摘要

大剂量噻替派联合自体骨髓挽救疗法是几种实体瘤中一种新的、有前景的治疗方式。我们将此方案用于一名小儿患者,该患者在“8合1”化疗期间发生了第三次复发性脑恶性少突胶质细胞瘤。静脉注射噻替派总剂量达到1125 mg/m²后,我们实现了完全缓解。噻替派对中枢神经系统有良好的穿透性,这使其对化学敏感的脑肿瘤可能有用,并且利用自体骨髓挽救,可接受的毒性下给予一个疗程的大剂量噻替派。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验